Accelerate Diagnostics (NASDAQ:AXDX) Rating Lowered to Sell at BidaskClub

Share on StockTwits

Accelerate Diagnostics (NASDAQ:AXDX) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday, BidAskClub reports.

A number of other brokerages have also issued reports on AXDX. BTIG Research reaffirmed a “hold” rating on shares of Accelerate Diagnostics in a report on Sunday, May 12th. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Finally, ValuEngine raised shares of Zillow Group from a “hold” rating to a “buy” rating in a report on Thursday. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $19.67.

Accelerate Diagnostics stock opened at $19.05 on Friday. The business has a 50 day moving average price of $20.60. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -11.76 and a beta of 2.84. Accelerate Diagnostics has a 12-month low of $10.23 and a 12-month high of $24.75. The company has a quick ratio of 24.03, a current ratio of 25.36 and a debt-to-equity ratio of 2.86.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. Accelerate Diagnostics had a negative net margin of 1,352.80% and a negative return on equity of 130.94%. The business had revenue of $1.75 million during the quarter, compared to analyst estimates of $2.12 million. As a group, analysts predict that Accelerate Diagnostics will post -1.6 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of AXDX. Belpointe Asset Management LLC purchased a new position in shares of Accelerate Diagnostics in the first quarter valued at $5,728,000. Amundi Pioneer Asset Management Inc. grew its holdings in shares of Accelerate Diagnostics by 33.0% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 991,090 shares of the medical research company’s stock valued at $11,397,000 after purchasing an additional 246,000 shares in the last quarter. Raging Capital Management LLC purchased a new position in shares of Accelerate Diagnostics in the fourth quarter valued at $2,518,000. Griffin Asset Management Inc. grew its holdings in shares of Accelerate Diagnostics by 72.6% in the fourth quarter. Griffin Asset Management Inc. now owns 436,519 shares of the medical research company’s stock valued at $5,020,000 after purchasing an additional 183,626 shares in the last quarter. Finally, FMR LLC lifted its position in Accelerate Diagnostics by 25.1% in the fourth quarter. FMR LLC now owns 738,449 shares of the medical research company’s stock worth $8,492,000 after buying an additional 148,099 shares during the last quarter. 50.58% of the stock is owned by hedge funds and other institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Read More: What is the Federal Reserve?

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Synovus Financial  Now Covered by DA Davidson
Synovus Financial Now Covered by DA Davidson
Marriott Vacations Worldwide  Stock Rating Upgraded by JPMorgan Chase & Co.
Marriott Vacations Worldwide Stock Rating Upgraded by JPMorgan Chase & Co.
Financial Contrast: HITACHI CHEM CO/ADR  & OCADO GRP PLC/S
Financial Contrast: HITACHI CHEM CO/ADR & OCADO GRP PLC/S
Critical Contrast: Bloomin’ Brands  & Main Street Capital
Critical Contrast: Bloomin’ Brands & Main Street Capital
Michaels Companies’  Underperform Rating Reaffirmed at Bank of America
Michaels Companies’ Underperform Rating Reaffirmed at Bank of America
Metlife  Price Target Cut to $53.00
Metlife Price Target Cut to $53.00


 
© 2006-2019 Zolmax.